mRNA Synthesis and mRNA Manufacturing Market (2nd Edition), 2022-2035: Distribution by Type of Product (Drug Substances (APIs) and Drug Products (FDFs)), Application Area(s) (mRNA Vaccines and mRNA Therapeutics), Therapeutic Area(s) (Infectious Diseases, Oncological Disorders and Other Diseases) and Key Geographical Regions (North America, Europe, Asia-Pacific, Latin America, MENA and Rest of the World): Industry Trends and Global Forecasts, 2022-2035
The global mRNA manufacturing and mRNA synthesis market is estimated to reach USD 1.95 billion in 2023 and is anticipated to decline at a CAGR of -1.7% during the forecast period 2022-2035.
Over the next decade, market projections indicate a decline in the market size due to an expected decrease in demand for COVID vaccines until 2035. However, the emergence of messenger ribonucleic acid (mRNA) as a pivotal therapeutic method in modern healthcare is noteworthy. Since the onset of the COVID-19 pandemic, mRNA therapeutics and vaccine production have gained significant attention, presenting a groundbreaking approach to combat not only COVID-19 but also a range of other conditions such as oncological, infectious, and genetic disorders. Currently, there are more than 195 mRNA therapeutics and vaccines in different developmental stages or already available for various medical conditions.
This surge in mRNA-based treatments has led to a noticeable increase in the demand for mRNA production capabilities. The manufacturing of mRNA therapeutics and vaccines is complex and requires significant capital investment, along with specialized expertise. Consequently, developers of mRNA-based therapies and vaccines are actively exploring strategies to overcome existing challenges. One promising avenue among the available options is the outsourcing of production to mRNA Contract Development and Manufacturing Organizations (CDMOs).
Looking forward, as a greater number of RNA-based candidates progress through clinical phases and enter the market, we anticipate substantial growth in the mRNA synthesis and manufacturing market during the forecast period.
Report Coverage
Over the next decade, market projections indicate a decline in the market size due to an expected decrease in demand for COVID vaccines until 2035. However, the emergence of messenger ribonucleic acid (mRNA) as a pivotal therapeutic method in modern healthcare is noteworthy. Since the onset of the COVID-19 pandemic, mRNA therapeutics and vaccine production have gained significant attention, presenting a groundbreaking approach to combat not only COVID-19 but also a range of other conditions such as oncological, infectious, and genetic disorders. Currently, there are more than 195 mRNA therapeutics and vaccines in different developmental stages or already available for various medical conditions.
This surge in mRNA-based treatments has led to a noticeable increase in the demand for mRNA production capabilities. The manufacturing of mRNA therapeutics and vaccines is complex and requires significant capital investment, along with specialized expertise. Consequently, developers of mRNA-based therapies and vaccines are actively exploring strategies to overcome existing challenges. One promising avenue among the available options is the outsourcing of production to mRNA Contract Development and Manufacturing Organizations (CDMOs).
Looking forward, as a greater number of RNA-based candidates progress through clinical phases and enter the market, we anticipate substantial growth in the mRNA synthesis and manufacturing market during the forecast period.
Report Coverage
- An executive summary of the key insights captured during research. It offers a high-level view on the current state of the mRNA synthesis and contract manufacturing services market and its likely evolution in the short to mid-term and long term.
- Overview of mRNA, highlighting details on its structure and the historical evolution of mRNA vaccines. It also presents information on the in-vitro synthesis of mRNA, its applications in various therapeutic modalities and the challenges associated with the process. Additionally, it features a discussion on the commonly outsourced manufacturing operations and their advantages. .
- Detailed assessment of the overall market landscape of the companies offering mRNA custom synthesis services, based on several relevant parameters, such as year of establishment, company size, location of headquarters, type of service(s) offered, input for synthesis, type of purification method(s), scale of operation and GMP compliance.
- A detailed competitiveness analysis of mRNA custom synthesis service providers based on supplier strength and service strength
- A comprehensive assessment of the overall market landscape of mRNA contract manufacturing service providers, based on several relevant parameters, including year of establishment, company size, location of headquarters, location of manufacturing facilities, type of product(s) manufactured, type of service(s) offered and scale of operation.
- An in-depth company competitiveness analysis of mRNA contract manufacturing service providers based in North America, Europe and Asia-Pacific. The analysis compares the contract service providers on the basis of various parameters, such as their supply strength and service portfolio strength.
- A detailed overview of the current market landscape of companies engaged in the development of mRNA synthesis kits, based on several relevant parameters, such as type of enzyme, kit components, type of enzyme mix used, mRNA component modified, yield per reaction, number of reactions, reaction run time and kit price.
- A product competitiveness analysis of the mRNA synthesis kits, based on supplier power and product competitiveness
- Detailed profiles of the key players offering services for the synthesis and manufacturing of mRNA. and key mRNA synthesis kit providers. Each profile includes a brief overview of the company, along with information on the mRNA synthesis kits portfolio.
- A detailed analysis of completed, ongoing and planned clinical studies of mRNA therapeutics and vaccines, based on several relevant parameters, such as trial registration year, trial status, trial phase, target patient population, therapeutic area, type of sponsor / collaborator, leading industry players, and regional distribution of trials.
- An analysis of recent partnerships inked between stakeholders engaged in this domain, since 2014, covering acquisitions, manufacturing agreements, fill / finish service agreements, supply agreements, service alliance, and other relevant deals.
- A comprehensive analysis of over 35 mRNA-based therapeutics / vaccines developers that are likely to partner with mRNA contract manufacturing service providers.
- A comprehensive market forecast analysis, highlighting the future potential of the market till 2035. We have segregated the current and upcoming opportunity based on type of product (drug substances (APIs) and drug products (FDFs)), application areas (mRNA-based vaccines and mRNA-based therapeutics), therapeutic areas (infectious diseases, oncological disorders and other diseases), and key geographical regions (North America, Europe, Asia-Pacific, Latin America, MENA and rest of the world).
- Aldevron
- APExBIO
- Biomay
- BioNTech
- CELLSCRIPT
- CureVac
- biosynthesis
- eTheRNA, Eurogentec
- Jena Biosciences
- Moderna
- New England Biolabs
- Thermo Fisher Scientific
- TriLink BioTechnologies
1. PREFACE
1.1. Scope of the Report
1.2. Market Segmentations
1.3. Research Methodology
1.4. Key Questions Answered
1.5. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. An Overview of mRNA
3.2. Structure of mRNA
3.3. Evolution of mRNA Vaccines
3.4. mRNA Manufacturing Process
3.4.1. Chemical Synthesis of mRNA
3.4.2. In vitro Synthesis of mRNA
3.5. Applications of Chemically / in vitro Synthesized mRNA
3.6. Challenges Associated with mRNA Synthesis
3.7. Commonly Outsourced Manufacturing Operations
3.8. Advantages of Outsourcing Manufacturing Operations
4. MARKET LANDSCAPE: MRNA CUSTOM SYNTHESIS SERVICE PROVIDERS
4.1. mRNA Custom Synthesis Service Providers: Overall Market Landscape
4.1.1. Analysis by Year of Establishment
4.1.2. Analysis by Company Size
4.1.3. Analysis by Location of Headquarters
4.1.4. Analysis by Company Size and Location of Headquarters
4.1.5. Analysis by Type of Service(s) Offered
4.1.6. Analysis by Input for Synthesis
4.1.7. Analysis by Structural Modification
4.1.8. Analysis by Type of Purification Method(s)
4.1.9. Analysis by Application Area(s)
4.1.10. Analysis by Scale of Operation
4.1.11. mRNA Custom Synthesis Service Providers: Information on Length (Base Pair) of mRNA Manufactured
4.1.12. mRNA Custom Synthesis Service Providers: Information on mRNA Synthesis / Manufacturing Capacity
5. MRNA CUSTOM SYNTHESIS SERVICE PROVIDERS: COMPANY COMPETITIVENESS ANALYSIS
5.1. Key Parameters and Scores
5.2. Methodology
5.3. Competitiveness Analysis: Small Companies
5.4. Competitiveness Analysis: Mid-Sized Companies
5.5. Competitiveness Analysis: Large Companies
6. MARKET LANDSCAPE: MRNA CONTRACT MANUFACTURING SERVICE PROVIDERS
6.1. mRNA Contract Manufacturing Service Providers: Overall Market Landscape
6.1.1. Analysis by Year of Establishment
6.1.2. Analysis by Company Size
6.1.3. Analysis by Location of Headquarters
6.1.4. Analysis by Company Size and Location of Headquarters
6.1.5. Analysis by Location of Manufacturing Facility
6.1.6. Analysis by Type of Product(s) Manufactured
6.1.7. Analysis by Type of Service(s) Offered
6.1.8. Analysis by Scale of Operation
7. MRNA CONTRACT MANUFACTURING SERVICE PROVIDERS (MRNA CDMO): COMPANY COMPETITIVENESS ANALYSIS
7.1. Methodology
7.2. Company Competitiveness Analysis: mRNA Contract Manufacturing Service Providers based in North America
7.3. Company Competitiveness Analysis: mRNA Contract Manufacturing Service Providers based in Europe
7.4. Company Competitiveness Analysis: mRNA Contract Manufacturing Service Providers based in Asia-Pacific
8. MARKET LANDSCAPE: MRNA SYNTHESIS KIT PROVIDERS
8.1. mRNA Synthesis Kits: Overall Market Landscape
8.1.1. Analysis by Kit Components
8.1.2. Analysis by Type of Enzyme
8.1.3. Analysis by Type of Enzyme Mix Used
8.1.4. Analysis by mRNA Component Modified
8.1.5. Analysis by Yield per Reaction
8.1.6. Analysis by Number of Reactions
8.1.7. Analysis by Reaction Run-Time
8.1.8. Analysis by Price of Kits
8.1.9. Most Active Players: Analysis by Number of mRNA Synthesis Kits Offered
8.2. mRNA Synthesis Kits: Developer Landscape
8.2.1. Analysis by Year of Establishment
8.2.2. Analysis by Company Size
8.2.3. Analysis by Location of Headquarters
9. MRNA SYNTHESIS KITS: PRODUCT COMPETITIVENESS ANALYSIS
9.1. Methodology
9.2. Product Competitiveness Analysis: mRNA Synthesis Kits
10. COMPANY PROFILES: MRNA SYNTHESIS AND MANUFACTURING SERVICE PROVIDERS
10.1. Aldevron
10.1.1. Company Overview
10.1.2. mRNA Synthesis Focused Services Portfolio
10.1.3. Recent Developments and Future Outlook
10.2. Biomay
10.2.1. Company Overview
10.2.2. mRNA Synthesis Focused Services Portfolio
10.2.3. Recent Developments and Future Outlook
10.3. bioSYNTHESIS
10.3.1. Company Overview
10.3.2. mRNA Synthesis Focused Services Portfolio
10.3.3. Future Outlook
10.4. eTheRNA
10.4.1. Company Overview
10.4.2. mRNA Synthesis Focused Services Portfolio
10.4.3. Recent Developments and Future Outlook
10.5. Eurogentec
10.5.1. Company Overview
10.5.2. mRNA Synthesis Focused Services Portfolio
10.5.3. Recent Developments and Future Outlook
10.6. TriLink BioTechnologies
10.6.1. Company Overview
10.6.2. mRNA Synthesis Focused Services Portfolio
10.6.3. Recent Developments and Future Outlook
11. COMPANY PROFILES: MRNA SYNTHESIS KIT PROVIDERS
11.1. APExBIO
11.1.1. Company Overview
11.1.2. mRNA Synthesis Kits Portfolio
11.2. CELLSCRIPT
11.2.1. Company Overview
11.2.2. mRNA Synthesis Kits Portfolio
11.3. Jena Biosciences
11.3.1. Company Overview
11.3.2. mRNA Synthesis Kits Portfolio
11.4. New England Biolabs
11.4.1. Company Overview
11.4.2. mRNA Synthesis Kits Portfolio
11.5. Thermo Fisher Scientific
11.5.1. Company Overview
11.5.2. mRNA Synthesis Kits Portfolio
12. CLINICAL TRIAL ANALYSIS
12.1. Methodology
12.2. mRNA-based Therapeutics / Vaccines: Clinical Trial Analysis
12.2.1. Analysis by Trial Registration Year
12.2.2 Analysis by Trial Status
12.2.3. Analysis by Trial Registration Year and Patients Enrolled
12.2.4. Analysis by Trial Registration Year and Trial Status
12.2.5. Analysis by Trial Phase
12.2.6. Analysis by Target Patient Population
12.2.7. Analysis by Therapeutic Area
12.2.8. Analysis by Type of Sponsor / Collaborator
12.2.9. Most Active Players: Analysis by Number of Trials
12.2.10. Analysis by Region
13. PARTNERSHIP AND COLLABORATIONS
13.1. Partnership Models
13.2. mRNA Synthesis and Manufacturing: Partnerships and Collaborations
13.1.1. Analysis by Year of Partnership
13.1.2. Analysis by Type of Partnership
13.1.3. Analysis by Year and Type of Partnership
13.1.4. Analysis by Type of Product
13.1.5. Analysis by Type of Partner
13.1.6. Most Active Players: Analysis by Number of Partnerships
13.1.7. Analysis by Local and International Agreements
13.1.8. Analysis by Intercontinental and Intracontinental Agreements
13.1.9. Analysis by Region
14. LIKELY PARTNERS ANALYSIS
14.1. Methodology
14.2. Likely Partners based in North America
14.2.1 Most Likely Partners based in North America
14.3. Likely Partners based
14.3.1 Most Likely Partners based in Europe
14.4. Likely Partners based in Asia Pacific and Rest of the World
14.4.1 Most Likely Partners based in Asia Pacific and Rest of the World
15. BIG PHARMA INITIATIVES
15.1. Methodology
15.2. Big Pharma Players: List of mRNA-based Therapeutics / Vaccines Focused Initiatives
15.3. Competitive Benchmarking of Big Pharma Players
15.3.1. Harvey Ball Analysis
15.3.2. Spider Web Analysis
16. MARKET FORECAST
16.1. Chapter Overview
16.2. Key Assumptions and Forecast Methodology
16.3. Global mRNA Synthesis and mRNA Manufacturing Market, 2022-2035
16.3.1. mRNA Synthesis and mRNA Manufacturing Market, 2022-2035: Distribution by Type of Product
16.3.1.1. mRNA Synthesis and mRNA Manufacturing Market for Drug Substances (APIs), 2022-2035
16.3.1.2. mRNA Synthesis and mRNA Manufacturing Market for Drug Products (FDFs), 2022-2035
16.3.2. mRNA Synthesis and Manufacturing Market, 2022-2035: Distribution by Application Area,
16.3.2.1. mRNA Synthesis and Manufacturing Market for mRNA-based Vaccines, 2022-2035
16.3.2.2. mRNA Synthesis and Manufacturing Market for mRNA-based Therapeutics, 2022-2035
16.3.3. mRNA Synthesis and Manufacturing Market: Distribution by Therapeutic Area, 2022, 2025 and 2035
16.3.3.1. mRNA Synthesis and Manufacturing Market for Infectious Diseases, 2022-2035
16.3.3.1. mRNA Synthesis and Manufacturing Market for Oncological Disorders, 2022-2035
16.3.3.1. mRNA Synthesis and Manufacturing Market for Other Diseases, 2022-2035
16.3.4. mRNA Synthesis and Manufacturing Market: Distribution by Geography, 2025 and 2035 (USD Billion)
16.3.4.1. mRNA Synthesis and Manufacturing Market in North America, 2022-2035
16.3.4.2. mRNA Synthesis and Manufacturing Market in Europe, 2022-2035
16.3.4.3. mRNA Synthesis and Manufacturing Market in Asia Pacific, 2022-2035
16.3.4.4. mRNA Synthesis and Manufacturing Market in Latin America, 2022-2035
16.3.4.5. mRNA Synthesis and Manufacturing Market in MENA, 2022-2035
16.3.4.6. mRNA Synthesis and Manufacturing Market in Rest of the World, 2022-2035
17. EXECUTIVE INSIGHTS
18. APPENDIX 1: TABULATED DATA
19. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
1.1. Scope of the Report
1.2. Market Segmentations
1.3. Research Methodology
1.4. Key Questions Answered
1.5. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. An Overview of mRNA
3.2. Structure of mRNA
3.3. Evolution of mRNA Vaccines
3.4. mRNA Manufacturing Process
3.4.1. Chemical Synthesis of mRNA
3.4.2. In vitro Synthesis of mRNA
3.5. Applications of Chemically / in vitro Synthesized mRNA
3.6. Challenges Associated with mRNA Synthesis
3.7. Commonly Outsourced Manufacturing Operations
3.8. Advantages of Outsourcing Manufacturing Operations
4. MARKET LANDSCAPE: MRNA CUSTOM SYNTHESIS SERVICE PROVIDERS
4.1. mRNA Custom Synthesis Service Providers: Overall Market Landscape
4.1.1. Analysis by Year of Establishment
4.1.2. Analysis by Company Size
4.1.3. Analysis by Location of Headquarters
4.1.4. Analysis by Company Size and Location of Headquarters
4.1.5. Analysis by Type of Service(s) Offered
4.1.6. Analysis by Input for Synthesis
4.1.7. Analysis by Structural Modification
4.1.8. Analysis by Type of Purification Method(s)
4.1.9. Analysis by Application Area(s)
4.1.10. Analysis by Scale of Operation
4.1.11. mRNA Custom Synthesis Service Providers: Information on Length (Base Pair) of mRNA Manufactured
4.1.12. mRNA Custom Synthesis Service Providers: Information on mRNA Synthesis / Manufacturing Capacity
5. MRNA CUSTOM SYNTHESIS SERVICE PROVIDERS: COMPANY COMPETITIVENESS ANALYSIS
5.1. Key Parameters and Scores
5.2. Methodology
5.3. Competitiveness Analysis: Small Companies
5.4. Competitiveness Analysis: Mid-Sized Companies
5.5. Competitiveness Analysis: Large Companies
6. MARKET LANDSCAPE: MRNA CONTRACT MANUFACTURING SERVICE PROVIDERS
6.1. mRNA Contract Manufacturing Service Providers: Overall Market Landscape
6.1.1. Analysis by Year of Establishment
6.1.2. Analysis by Company Size
6.1.3. Analysis by Location of Headquarters
6.1.4. Analysis by Company Size and Location of Headquarters
6.1.5. Analysis by Location of Manufacturing Facility
6.1.6. Analysis by Type of Product(s) Manufactured
6.1.7. Analysis by Type of Service(s) Offered
6.1.8. Analysis by Scale of Operation
7. MRNA CONTRACT MANUFACTURING SERVICE PROVIDERS (MRNA CDMO): COMPANY COMPETITIVENESS ANALYSIS
7.1. Methodology
7.2. Company Competitiveness Analysis: mRNA Contract Manufacturing Service Providers based in North America
7.3. Company Competitiveness Analysis: mRNA Contract Manufacturing Service Providers based in Europe
7.4. Company Competitiveness Analysis: mRNA Contract Manufacturing Service Providers based in Asia-Pacific
8. MARKET LANDSCAPE: MRNA SYNTHESIS KIT PROVIDERS
8.1. mRNA Synthesis Kits: Overall Market Landscape
8.1.1. Analysis by Kit Components
8.1.2. Analysis by Type of Enzyme
8.1.3. Analysis by Type of Enzyme Mix Used
8.1.4. Analysis by mRNA Component Modified
8.1.5. Analysis by Yield per Reaction
8.1.6. Analysis by Number of Reactions
8.1.7. Analysis by Reaction Run-Time
8.1.8. Analysis by Price of Kits
8.1.9. Most Active Players: Analysis by Number of mRNA Synthesis Kits Offered
8.2. mRNA Synthesis Kits: Developer Landscape
8.2.1. Analysis by Year of Establishment
8.2.2. Analysis by Company Size
8.2.3. Analysis by Location of Headquarters
9. MRNA SYNTHESIS KITS: PRODUCT COMPETITIVENESS ANALYSIS
9.1. Methodology
9.2. Product Competitiveness Analysis: mRNA Synthesis Kits
10. COMPANY PROFILES: MRNA SYNTHESIS AND MANUFACTURING SERVICE PROVIDERS
10.1. Aldevron
10.1.1. Company Overview
10.1.2. mRNA Synthesis Focused Services Portfolio
10.1.3. Recent Developments and Future Outlook
10.2. Biomay
10.2.1. Company Overview
10.2.2. mRNA Synthesis Focused Services Portfolio
10.2.3. Recent Developments and Future Outlook
10.3. bioSYNTHESIS
10.3.1. Company Overview
10.3.2. mRNA Synthesis Focused Services Portfolio
10.3.3. Future Outlook
10.4. eTheRNA
10.4.1. Company Overview
10.4.2. mRNA Synthesis Focused Services Portfolio
10.4.3. Recent Developments and Future Outlook
10.5. Eurogentec
10.5.1. Company Overview
10.5.2. mRNA Synthesis Focused Services Portfolio
10.5.3. Recent Developments and Future Outlook
10.6. TriLink BioTechnologies
10.6.1. Company Overview
10.6.2. mRNA Synthesis Focused Services Portfolio
10.6.3. Recent Developments and Future Outlook
11. COMPANY PROFILES: MRNA SYNTHESIS KIT PROVIDERS
11.1. APExBIO
11.1.1. Company Overview
11.1.2. mRNA Synthesis Kits Portfolio
11.2. CELLSCRIPT
11.2.1. Company Overview
11.2.2. mRNA Synthesis Kits Portfolio
11.3. Jena Biosciences
11.3.1. Company Overview
11.3.2. mRNA Synthesis Kits Portfolio
11.4. New England Biolabs
11.4.1. Company Overview
11.4.2. mRNA Synthesis Kits Portfolio
11.5. Thermo Fisher Scientific
11.5.1. Company Overview
11.5.2. mRNA Synthesis Kits Portfolio
12. CLINICAL TRIAL ANALYSIS
12.1. Methodology
12.2. mRNA-based Therapeutics / Vaccines: Clinical Trial Analysis
12.2.1. Analysis by Trial Registration Year
12.2.2 Analysis by Trial Status
12.2.3. Analysis by Trial Registration Year and Patients Enrolled
12.2.4. Analysis by Trial Registration Year and Trial Status
12.2.5. Analysis by Trial Phase
12.2.6. Analysis by Target Patient Population
12.2.7. Analysis by Therapeutic Area
12.2.8. Analysis by Type of Sponsor / Collaborator
12.2.9. Most Active Players: Analysis by Number of Trials
12.2.10. Analysis by Region
13. PARTNERSHIP AND COLLABORATIONS
13.1. Partnership Models
13.2. mRNA Synthesis and Manufacturing: Partnerships and Collaborations
13.1.1. Analysis by Year of Partnership
13.1.2. Analysis by Type of Partnership
13.1.3. Analysis by Year and Type of Partnership
13.1.4. Analysis by Type of Product
13.1.5. Analysis by Type of Partner
13.1.6. Most Active Players: Analysis by Number of Partnerships
13.1.7. Analysis by Local and International Agreements
13.1.8. Analysis by Intercontinental and Intracontinental Agreements
13.1.9. Analysis by Region
14. LIKELY PARTNERS ANALYSIS
14.1. Methodology
14.2. Likely Partners based in North America
14.2.1 Most Likely Partners based in North America
14.3. Likely Partners based
14.3.1 Most Likely Partners based in Europe
14.4. Likely Partners based in Asia Pacific and Rest of the World
14.4.1 Most Likely Partners based in Asia Pacific and Rest of the World
15. BIG PHARMA INITIATIVES
15.1. Methodology
15.2. Big Pharma Players: List of mRNA-based Therapeutics / Vaccines Focused Initiatives
15.3. Competitive Benchmarking of Big Pharma Players
15.3.1. Harvey Ball Analysis
15.3.2. Spider Web Analysis
16. MARKET FORECAST
16.1. Chapter Overview
16.2. Key Assumptions and Forecast Methodology
16.3. Global mRNA Synthesis and mRNA Manufacturing Market, 2022-2035
16.3.1. mRNA Synthesis and mRNA Manufacturing Market, 2022-2035: Distribution by Type of Product
16.3.1.1. mRNA Synthesis and mRNA Manufacturing Market for Drug Substances (APIs), 2022-2035
16.3.1.2. mRNA Synthesis and mRNA Manufacturing Market for Drug Products (FDFs), 2022-2035
16.3.2. mRNA Synthesis and Manufacturing Market, 2022-2035: Distribution by Application Area,
16.3.2.1. mRNA Synthesis and Manufacturing Market for mRNA-based Vaccines, 2022-2035
16.3.2.2. mRNA Synthesis and Manufacturing Market for mRNA-based Therapeutics, 2022-2035
16.3.3. mRNA Synthesis and Manufacturing Market: Distribution by Therapeutic Area, 2022, 2025 and 2035
16.3.3.1. mRNA Synthesis and Manufacturing Market for Infectious Diseases, 2022-2035
16.3.3.1. mRNA Synthesis and Manufacturing Market for Oncological Disorders, 2022-2035
16.3.3.1. mRNA Synthesis and Manufacturing Market for Other Diseases, 2022-2035
16.3.4. mRNA Synthesis and Manufacturing Market: Distribution by Geography, 2025 and 2035 (USD Billion)
16.3.4.1. mRNA Synthesis and Manufacturing Market in North America, 2022-2035
16.3.4.2. mRNA Synthesis and Manufacturing Market in Europe, 2022-2035
16.3.4.3. mRNA Synthesis and Manufacturing Market in Asia Pacific, 2022-2035
16.3.4.4. mRNA Synthesis and Manufacturing Market in Latin America, 2022-2035
16.3.4.5. mRNA Synthesis and Manufacturing Market in MENA, 2022-2035
16.3.4.6. mRNA Synthesis and Manufacturing Market in Rest of the World, 2022-2035
17. EXECUTIVE INSIGHTS
18. APPENDIX 1: TABULATED DATA
19. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
